Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An update from Omega Therapeutics ( (OMGA) ) is now available.
On January 22, 2025, Ravi Mehrotra, Ph.D. and Robert L. Rosiello resigned from the Board of Directors of Omega Therapeutics. Subsequently, on January 24, 2025, Jeffrey T. Varsalone was appointed as a Class I director, receiving a monthly cash fee and indemnification as part of his agreement with the company. Additionally, Richard Kender was moved from Class III to Class II in order to rebalance the board’s classes, with his service deemed uninterrupted for all purposes.
More about Omega Therapeutics
YTD Price Performance: -43.35%
Average Trading Volume: 302,396
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $28.18M
Learn more about OMGA stock on TipRanks’ Stock Analysis page.
